TRCT
CELU icon

Tower Research Capital (TRC)’s Celularity CELU Stock Holding History

Tower Research Capital (TRC)’s Portfolio CELU Stock Details CELU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.06K Buy
5,111
+1,847
+57% +$1.77K ﹤0.01% 4578
2026
Q1 		$4.34K Sell
3,264
-1,734
-35% -$2.19K ﹤0.01% 4206
2025
Q4 		$5.55K Sell
4,998
-1,846
-27% -$3.31K ﹤0.01% 4114
2025
Q3 		$14.2K Buy
6,844
+3,789
+124% +$10.6K ﹤0.01% 3621
2025
Q2 		$5.99K Buy
+3,055
New +$5.56K ﹤0.01% 4135
2024
Q4 		– Sell
-1,592
Closed -$4.73K – 5715
2024
Q3 		$4.73K Sell
1,592
-383
-19% -$1.13K ﹤0.01% 4438
2024
Q2 		$6.18K Sell
1,975
-4,940
-71% -$17.1K ﹤0.01% 4610
2024
Q1 		$36.2K Buy
6,915
+4,081
+144% +$16.8K ﹤0.01% 2495
2023
Q4 		$7K Sell
2,834
-2,239
-44% -$4.86K ﹤0.01% 4676
2023
Q3 		$11.3K Buy
5,073
+3,506
+224% +$12.6K ﹤0.01% 4008
2023
Q2 		$8.35K Sell
1,567
-113
-7% -$724 ﹤0.01% 4442
2023
Q1 		$10K Sell
1,680
-45
-3% -$362 ﹤0.01% 4332
2022
Q4 		$22K Buy
1,725
+1,110
+180% +$20.5K ﹤0.01% 3033
2022
Q3 		$14K Sell
615
-894
-59% -$27.1K ﹤0.01% 4206
2022
Q2 		$51K Buy
1,509
+1,219
+420% +$99K ﹤0.01% 2854
2022
Q1 		$25K Buy
+290
New +$17.4K ﹤0.01% 3319
2021
Q3 		– Sell
-52
Closed -$5K – 5795
2021
Q2 		$5K Sell
52
-19
-27% -$1.93K ﹤0.01% 4692
2021
Q1 		$7K Buy
71
+51
+255% +$5.23K ﹤0.01% 4515
2020
Q4 		$2K Buy
+20
New +$2.13K ﹤0.01% 4870
2020
Q3 		– Sell
-112
Closed -$11K – 4834
2020
Q2 		$11K Buy
+112
New +$11.1K ﹤0.01% 3959

Other funds holding CELU

CVSC
C.V. Starr & Co New York $187M AUM 26.03% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
BFO
Biltmore Family Office Charlotte, North Carolina $761M AUM 31.91% 1-Year Est. Return

Tower Research Capital (TRC)'s CELU Position: Q2 2026 in Review

Tower Research Capital (TRC) increased its Celularity (CELU) stake by 57% in Q2 2026, buying an estimated $1.77K and bringing the position to 5,111 shares worth $3.06K. The position accounts for ﹤0.01% of the portfolio, ranked #4578.

Tower Research Capital (TRC) first reported a position in CELU in Q2 2020 and has held it in 20 quarters since. The position peaked at $51K in Q2 2022. 39 funds tracked by Wall St. Rank hold CELU as of Q2 2026.

  • Tower Research Capital (TRC) held 5,111 shares of Celularity worth $3.06K as of Q2 2026.
  • Tower Research Capital (TRC) bought 1,847 Celularity shares in Q2 2026, an estimated $1.77K.
  • Celularity made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #4578 holding.
  • Tower Research Capital (TRC) first reported a position in Celularity in Q2 2020 and has held it in 20 quarters since.
  • Tower Research Capital (TRC)'s Celularity position peaked at $51K in Q2 2022.
  • 39 funds tracked by Wall St. Rank held Celularity as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.